You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

Investigational Drug Information for Dorzagliatin


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Dorzagliatin?

Dorzagliatin is an investigational drug.

There have been 7 clinical trials for Dorzagliatin. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2022.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Glucose Intolerance, and Diabetes Mellitus. The leading clinical trial sponsors are Hua Medicine Limited, Chinese University of Hong Kong, and University of Virginia.

There are two US patents protecting this investigational drug and fifty-two international patents.

Recent Clinical Trials for Dorzagliatin
TitleSponsorPhase
Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGTChinese University of Hong KongPhase 1/Phase 2
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase ActivityUniversity of VirginiaPhase 3
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in Individuals With Recent-onset Type 2 Diabetes and Monogenic DiabetesChinese University of Hong KongPhase 2

See all Dorzagliatin clinical trials

Clinical Trial Summary for Dorzagliatin

Top disease conditions for Dorzagliatin
Top clinical trial sponsors for Dorzagliatin

See all Dorzagliatin clinical trials

US Patents for Dorzagliatin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dorzagliatin ⤷  Sign Up Pyrrolidinone glucokinase activators Hoffmann-La Roche Inc. (Nutley, NJ) ⤷  Sign Up
Dorzagliatin ⤷  Sign Up Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine HUA MEDICINE (Grand Gayman, KY) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.